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Introduction: Children with juvenile idiopathic arthritis (JIA) often have impaired growth and
short stature. There is evidence that the therapeutic use of growth hormone (GH) is useful
and safe in these patients.
Objective: To analyze the effects of GH use in patients with JIA.
Method: A systematic review of the literature over the last 18 years in Medline and Embase
databases. The criteria were analyzed independently by the researchers. We  used the fol-
lowing keywords: “growth hormone”, “arthritis, juvenile”, “arthritis, rheumatoid”, “child”
and “adolescent”.
Results: Among the 192 identiﬁed articles, 20 corresponded to the inclusion criteria. Seven-
teen  longitudinal studies and 3 case reports were found. Most studies analyzed observed
increased growth, muscle mass and bone mass using GH. Adverse effects observed were
glucose intolerance, diabetes, bone deformities, osteonecrosis, reactivation of the disease
and low ﬁnal height.
Conclusion: The majority of studies reported positive effects after the therapeutic use of GH,
but  some variability in response to treatment was observed. The combination of growthhormone with other drugs seems to be a good option.
© 2016 Published by Elsevier Editora Ltda. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Please cite this article in press as: Frittoli RB, et al. Effects of the use of growth hormone in children and adolescents with juvenile idiopathic
arthritis: a systematic review. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.07.009
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Efeitos  do  uso  do  hormônio  de  crescimento  em  crianc¸as e  adolescentes
com  artrite  idiopática  juvenil:  revisão  sistemática
Palavras-chave:
Artrite idiopática juvenil
Hormônio de crescimento
Crianc¸as
Adolescentes
r  e  s  u  m  o
Introduc¸ão: Crianc¸as com artrite idiopática juvenil (AIJ) frequentemente apresentam prejuízo
no  crescimento e baixa estatura. Existem evidências de que o uso terapêutico do hormônio
de  crescimento (GH) é útil e seguro nesses pacientes.
Objetivo: Analisar os efeitos do uso de GH em pacientes com AIJ.
Método: Fez-se revisão sistemática da literatura nos últimos 18 anos, nas bases de dados
Medline e Embase. Os critérios foram analisados pelos pesquisadores de forma inde-
pendente. Usaram-se os seguintes descritores: growth hormone, arthritis, juvenile, arthritis,
rheumatoid, child e adolescent.
Resultados: Entre os 192 artigos identiﬁcados, 20 corresponderam aos critérios de inclusão.
Foram encontrados 17 estudos longitudinais e três relatos de casos. A maioria dos estudos
analisados observou um aumento de crescimento, massa muscular e massa óssea com o uso
do  GH. Os efeitos adversos observados foram intolerância à glicose, diabetes, deformidades
ósseas, osteonecrose, reativac¸ão da doenc¸a e altura ﬁnal baixa.
Conclusão: A maioria dos estudos relatou efeitos positivos após uso terapêutico do GH, porém
certa variabilidade na resposta ao tratamento foi observada. A combinac¸ão do hormônio de
crescimento com outros medicamentos parece ser uma boa opc¸ão.
©  2016 Publicado por Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma
c¸a  Clicen
Introduction
Juvenile idiopathic arthritis (JIA) is an autoimmune disease
and the leading cause of chronic arthritis in pediatric patients.
Its annual incidence varies from 2 to 20 cases/100,000 inhabi-
tants, with a prevalence of 15–150 cases/100,000 inhabitants.1
Its main features are chronic arthritis, and in some cases
being associated with multisystem involvement and progres-
sion to joint limitations and permanent functional disability.2
The diagnosis of JIA is based on criteria of the Interna-
tional League of Associations for Rheumatology (ILAR) and
requires the presence of arthritis in children and adolescents
aged under 16 years, that persists for at least six weeks, when
excluding the presence of other causes of chronic arthritis.3
According to the literature, the most frequent JIA subtypes
are oligoarticular JIA (50–60%), polyarticular JIA (30–35%) and
systemic JIA (10–20%).4
Children with JIA often exhibit an inadequate growth
and short stature, and these effects relate to the extent of
organs involved, with the activity and extent of the disease,
malnutrition, malabsorption, increased catabolism, associ-
ated complications, a constant inﬂammatory process, and
effects of the use of certain medications, being the most rel-
evant of them the glucocorticoids.5–8 Several studies have
observed improved growth and height rates in patients with
JIA treated with growth hormone (GH).5,9–25 There are sev-
eral indications of the use of GH approved for treatment of
JIA; however, the use of this hormone can result in adverse
events,26 including negative variability in response to treat-
ment which has been observed in some studies of patientsPlease cite this article in press as: Frittoli RB, et al. Effects of the use of gr
arthritis: a systematic review. Rev Bras Reumatol. 2016. http://dx.doi.org/1
with JIA.9,10,14,19,20,24,25,27,28
Due to the high cost and potential side effects,9,10,20,27 there
are controversies about the ideal indication, the dose, andC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
duration of the GH therapy in JIA.26 An understanding the indi-
cations for therapy with growth hormone and its controversies
can facilitate the evaluation of the patient and his/her referral
to the best treatment.26,29,30 The aim of this study is to analyze
the various effects of GH use in patients with JIA, based on the
literature review.
Methods
This study consists of a systematic literature review, after
a search conducted during the months of July and August
2015, of studies published in the last 18 years (1998–2015).
The search of the references was conducted through an elec-
tronic database (Medline and Embase) exploration and of the
reference list of identiﬁed articles by three researchers inde-
pendently. References that met  the inclusion criteria were
evaluated, regardless of their journal. The selection of the
descriptors used in the review process was conducted in con-
sultation with DeCS (Health Sciences Descriptors byBIREME).
In the search, the following descriptors in Portuguese and
English were considered: “growth hormone”, “arthritis, juve-
nile”, “arthritis, rheumatoid,” “child” and “adolescent”.31
In the electronic database MedLine, 104 studies were iden-
tiﬁed, and Embase 88 studies were identiﬁed, totaling 192
studies. 64 matching studies were identiﬁed, and 128 articles
were tabulated on a spreadsheet with data related to the title
of the study, journal, year, age group studied, study idiom,
evaluated diseases, disease duration, treatment time, thera-
peutic dose, and possible use of growth hormone as a therapy.owth hormone in children and adolescents with juvenile idiopathic
0.1016/j.rbre.2016.07.009
The inclusion criteria were as follows: (1) Original arti-
cles; (2) Articles in Portuguese or in English idiom; (3) Articles
which used growth hormone as a therapy; (4) Articles that
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Selected studies
(n=128)
Replicated studies,
removed (n=25)
Pubmed and embase -
electronic search
(n=192)
Identified studies
(summary and title)
(n=153)
Identification
Screening
Eligibility
Included
Excluded studies (n=109):
GH not used as therapy (n=61)
Not evaluated JIA (n=9)
Studies published over than 13 years ago (n=14)
Reviews (n=15)
Animal studies (n=1)
Other Language (n=8)
Unavailable journals (n=1)
Articles included
in this study
(n=20)
Articles in reference
lists of identified articles
(n=1)
Full-text articles to
assess eligibility
(n=19)
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valuated patients with JIA; (5) Articles that included children
nd adolescents in their sample (Fig. 1).
esults
wenty studies were included, of which 17 had longitudinal
esign5,11–25,28 and three were case reports.9,10,27 A total of
59 patients with JIA (systemic, polyarticular, and oligoartic-
lar) were treated with GH, with doses ranging from 0.028 to
.067 mg/kg/day, and aged from 4 to 17 years; the treatment
ime ranged from 9 months to 6 years (Tables 1 and 2).
After use of GH, an increased growth of JIA patients
as demonstrated in 80% of the studies,5,11–25 andPlease cite this article in press as: Frittoli RB, et al. Effects of the use of gr
arthritis: a systematic review. Rev Bras Reumatol. 2016. http://dx.doi.org/1
5% reported signiﬁcant improvement in pubertal
evelopment.11–13,16,17,24,25
Among the positive effects of the treatment, 30%
f the studies reported improvement in bone mineral process of selection of articles.
density and bone metabolism.12,17,19,21,23 In comparison
with pre-treatment values, it was reported that the forma-
tion and resorption markers increased signiﬁcantly during
treatment,17,21,23 and that the plasma level of osteocalcin was
the best variable predictive of growth in JIA patients who  had
been treated with GH.21
One study found that the fat level has remained stable,
with no signiﬁcant changes versus patients who  did not use
GH;12 but in 4 (20%) studies, lean mass increase and fat mass
decrease were observed.15,19,23,25
Regarding blood glucose and glucose intolerance in 5 (25%)
studies,14,19,24,25,28 a signiﬁcant increase in fasting blood glu-
cose was noted in patients treated with GH versus control
group, which led, in some cases, to the possible development
19,24,25,28 25,28owth hormone in children and adolescents with juvenile idiopathic
0.1016/j.rbre.2016.07.009
of insulin resistance, and to diabetes. Increases in
glycosylated hemoglobin were also described.19,24,25
Development of osteonecrosis10 was observed in one
case report; in another report, one patient developed severe
Please
 cite
 th
is
 article
 in
 p
ress
 as:
 Frittoli
 R
B
,
 et
 al.
 Effects
 of
 th
e
 u
se
 of
 grow
th
 h
orm
on
e
 in
 ch
ild
ren
 an
d
 ad
olescen
ts
 w
ith
 ju
ven
ile
 id
iop
ath
ic
arth
ritis:
 a
 system
atic
 review
.
 R
ev
 B
ras
 R
eu
m
atol.
 2016.
 h
ttp
://d
x.d
oi.org/10.1016/j.rbre.2016.07.009
A
RTICLE IN PRESS
R
B
R
E-306;
 
N
o.
 of
 Pages
 7
4
 
r
 e
 v
 b
 r
 a
 s
 r
 e
 u
 m
 a
 t
 o
 l
 .
 2
 0
 1
 6
;x
 x
 x
(x
 x
):xxx–xxx
Table 1 – Description of articles on Growth Hormone (GH) effects in patients with Juvenile Idiopathic Arthritis (JIA) (longitudinal studies): 1998–2015.
Article Sample Age
group
(years)
Disease
duration
(years)
GH  dose
(mg/kg/day)
Treatment
duration (years)
GH  effect
Bechtold, 201211
(Deutschland)
39 patients (systemic/polyarticular JIA)
24 controls
(8–13) ∼=5  0.047 6.32 ± 1.96 GH had positive effects on height and pubertal development
Bismuth E, 201028
(France)
43 patients (systemic/polyarticular JIA)
15 controls
(4–14)
(4–8)
3.9  ± 2.7
4.3 ± 2.9
0.065 3 GH combined with glucocorticoids was associated with a signiﬁcant
increase in fasting insulin level
Bechtold, 201012
(Deutschland)
12 patients (systemic/polyarticular JIA) (9–14) 8.49 ± 2.9 – 5.35 ± 0.7 Beneﬁts in anthropometric levels, and fat levels stabilized
Bechtold, 200713
(Deutschland)
31 patients (systemic/polyarticular JIA)
18 controls
(10–14)  3,7 ± 1,2 0.047 8.4 Patients reached the height within the standard target set
Simon, 200714
(France)
30 patients (systemic/polyarticular JIA) (7–12) – 0.065 3 Beneﬁts in anthropometric levels
Bone mineralization with no signiﬁcant difference
Increased blood glucose
Bechtold, 200515
(Deutschland)
17 patients (systemic/polyarticular JIA) (12–17) 8.2 ± 4.4 (0.036–0.047) 4 GH had positive and signiﬁcant effects on height and muscle mass
Saha, 200416
(Finland)
25 patients (12 polyarticular JIA, 10
oligoarticular JIA and 3 systemic JIA)
(8–11) – 0.033 0.5 (6 months) Patients with GH treatment grew faster versus control group
Bechtold, 200417
(Deutschland)
11 patients (systemic/polyarticular JIA) (9–11) 3.7 ± 1.4 0.047 4 Signiﬁcant increase in height, and improvement in bone remodeling
Bechtold, 200318
(Deutschland)
38 patients (systemic/polyarticular JIA) (5.5–13.8) ∼=3.8 (0.028–0.047) 4 Signiﬁcant increase in ﬁnal height
Simon, 200319
(France)
30 patients (systemic/polyarticular JIA) (6.8–13.0) 8.2
(4.5–15.6)
0.065 3 Improvement in growth rate
Increases in lean body mass and bone mineral density
Glucose intolerance observed in 6 patients
Increase of glycosylated hemoglobin
Simon, 20015
(France)
14 patients (systemic/polyarticular JIA) ∼=9.7 ∼=3  0.065 1 Improved growth rate and prevention of metabolic complications
Al-Mutair, 200020
(Saudi Arabia)
10 patients (systemic/polyarticular JIA) (6–15) – 0.027 1 and 3 Improved growth in the ﬁnal height
One patient developed deformities in both knees
Touati, 200021
(France)
14 patients (systemic/polyarticular JIA) (6–14) ∼=3 0.066 1 Signiﬁcant increases in bone resorption markers
Plasma level of osteocalcin was the best variable predictive of growth
Rooney, 200022
(England)
20 patients (systemic/polyarticular JIA) 7.6 – – 1 Improvement of bone metabolism and height
Simon, 200023
(France)
14 patients (systemic/polyarticular JIA) ∼=9  – 0.06 2 Increases in growth rate and lean mass
Increase in bone mineral density
Simon, 199924
(France)
14 patients (systemic/polyarticular JIA) (9–12) 3
(9 months
to ∼=8 years)
0.067 1 Improvement in growth rate
Decrease in glucose tolerance and increase in glycosylated
hemoglobin levels
Touati, 199825
(France)
14 patients (systemic/polyarticular JIA) ∼=9  – 0.066 1–2 Increase in growth
Increase in lean mass and decrease in fat mass
Increase of glucose tolerance and increase in glycosylated hemoglobin
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Table 2 – Description of articles on Growth Hormone (GH) effects in patients with Juvenile Idiopathic Arthritis (JIA) (case
reports): 1998–2015.
Article Sample Age
group
(years)
Disease
duration
(years ± SD)
GH  dose
(mg/kg/day)
Treatment
duration (years)
GH  effect
Kim, 20149
(South Korea)
1  patient
(Systemic JIA)
16 7 0.04 0.75 (9 months) GH had positive effects on
height
Possible effect of GH on the
reactivation of the disease
Nikishina, 201110
(Russia)
1  patient
(polyarticular JIA)
14 – 0.05 – GH had positive effects on
height
Possible effect of GH in the
development of
osteonecrosis
Pun, 201127
(Canada)
1  patient
(JIA + Autoimmune
16 13 – – Atypical ﬁndings including
growth hormone deﬁciency
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syndrome type 1)
eformity in both knees.20 In case reports, reactivation of the
isease in two studies9,10 and low ﬁnal height in one study
ere observed.27
iscussion
ecombinant GH has revolutionized the treatment of chil-
ren and adolescents with growth hormone deﬁciency and
ther growth disorders, but the clinical and ethical contro-
ersies remain, about the diagnostic approach in patients
ith JIA, as well as the optimal dose, duration, and expected
esults.11,12,19,26
The results obtained by many  longitudinal studies con-
rmed previously published data, that the treatment with GH
f patients with JIA allows positively affect the pubertal devel-
pment and ﬁnal height.5,11–25
It is known that the treatment instituted, particularly the
se of glucocorticoids, also compromise the growth, which
epends on other factors such as age of onset of the disease, its
everity, the patient’s response to treatment, time of adminis-
ration, and dose of the glucocorticoid administered.8
Bone formation and resorption markers increased signif-
cantly during the treatment with GH14,17,19,21–23; but a study
bserved loss of growth following the discontinuation of the
reatment.23 It is believed that a prolonged treatment with
H is needed, in order to allow an assessment of a positive
ffect of this hormone on the bone density and metabolism in
atients with JIA.10,14,17,19,23,25 The monitoring of patients to
heir ﬁnal height, besides bone mass evaluation, are needed
o better understand the potential beneﬁcial effect of GH
reatment.5,11–25,27
As to glucose intolerance, studies did not ﬁnd patients
ith abnormal glucose metabolism symptoms before use of
H.14,19,24,25,28 The metabolism of carbohydrates must be care-
ully monitored in JIA patients treated with GH, particularly
uring the acute phase of their disease. It is known that glu-
ocorticoids interfere with the GH/IGF-1 axis, decreasing thePlease cite this article in press as: Frittoli RB, et al. Effects of the use of gr
arthritis: a systematic review. Rev Bras Reumatol. 2016. http://dx.doi.org/1
H pulsatile secretion by increasing of somatostatin levels and
hat these pharmaceuticals also reduce the expression of GH
eceptors on hepatocytes, causing some degree of resistance
o GH, with a consequent reduction of IGF-1 levels.32,33even with use of the
treatment, short stature
Theoretically, GH not only regulates growth but also con-
trols the immune function, considering that it is not common
an occurrence of relapse of disease activity after several years
of remission without a deﬁnite cause.18,25 It has been ques-
tioned if GH was responsible for the reactivation of the disease
in those case reports presented in this paper.9,10
One study reported an atypical case of JIA, with short
stature after the use of GH; however, this result cannot be
generalized to other studies because the patient suffered from
other concomitant diseases.27
It should be stressed that JIA is a disease with multiple
clinical manifestations among affected individuals (a sys-
temic, polyarticular, oligoarticular, etc., onset). Thus, there are
no double-blind randomized controlled studies or trials with
placebo versus the use of GH. A better understanding of the
disease and more  effective treatments in recent years can radi-
cally change the growth status of these patients. Some authors
suggest that the treatment with GH is implemented in combi-
nation with other drugs, and biological drugs are among those
most favored.30
Conclusion
The studies published in recent years show improved growth
and height rates in JIA patients treated with GH.
Some variation in the response to treatment was observed;
in some cases, recovery in growth takes place, and in other
cases the treatment prevents the loss of height generally
observed during the natural course of the disease. The selec-
tion of the response depends on the initiation of treatment
with GH and the on disease severity and activity. The studies
presented in this review are singular, concerning the studied
factors (positive and negative effects) and cannot be general-
ized. The combination of growth hormone with other drugs
may be an option.owth hormone in children and adolescents with juvenile idiopathic
0.1016/j.rbre.2016.07.009
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